WHO Pharmaceuticals Newsletter 1998, No. 11&12
(1998; 10 pages)
Table des matières
Fermer ce répertoireRegulatory actions
Afficher le documentAcetylsalicylic acid and paracetamol: stricter controls: UK
Afficher le documentAlcohol warning: revised labelling of all OTC pain relievers & fever reducers: USA
Afficher le documentCamphor and/or menthol: warning concerning fire hazard: USA
Afficher le documentCholestin: determined to be an unapproved drug: USA
Afficher le documentCorticosteroids (inhaled and intranasal formulations): new labelling required for use in children: USA
Afficher le documentEphedrine and atropine: not accepted in final monographs for OTC internal analgesic or menstrual use: USA
Afficher le documentEritrityl tetranitrate: withdrawal of approval: lack of efficacy: USA
Afficher le documentL-desoxyephedrine (levmetamfetamine): added to monograph for OTC nasal decongestant drug products: USA
Afficher le documentMagnesium sulfate: revised labelling: UK
Afficher le documentNucleoside analogues: revised product information: hepatic steatosis and lactic acidosis: Portugal
Afficher le documentPovidone-iodine: warning concerning overdosage: Austria
Afficher le documentSoy protein and coronary heart disease: new health claim proposed: USA
Afficher le documentTick-borne encephalitis virus vaccine: paediatric formulation withdrawn: adverse reactions: Germany
Ouvrir ce répertoire et afficher son contenuDrug surveillance
Ouvrir ce répertoire et afficher son contenuNew developments
Ouvrir ce répertoire et afficher son contenuMedical devices
Ouvrir ce répertoire et afficher son contenuGeneral information
Ouvrir ce répertoire et afficher son contenuMedication errors
Ouvrir ce répertoire et afficher son contenuVeterinary medicine
 

L-desoxyephedrine (levmetamfetamine): added to monograph for OTC nasal decongestant drug products: USA

United States of America. The Food and Drug Administration has amended the final monograph for over-the-counter (OTC) nasal decongestant drug products to add the ingredient l-desoxyephedrine (levmetamfetamine) and to classify this ingredient as generally recognized as safe and effective for OTC use for the relief of nasal congestion caused by acute or chronic rhinitis. The agency is also removing the name “l-desoxyephedrine” from the list of nonmonograph active ingredients.

Reference: Federal Register 63(146): 40647-50 (1998).

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013